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Abstract
Background: Dysregulation of the expression/shuttling of the aquaporin-2 water channel (AQP2) and the epithelial
sodium channel (ENaC) in renal collecting duct principal cells has been found in animal models of hypertension.
We tested whether a similar dysregulation exists in essential hypertension.
Methods: We measured urinary excretion of AQP2 and ENaC b-subunit corrected for creatinine (u-AQP2CR,u -
ENaCb-CR), prostaglandin E2 (u-PGE2) and cyclic AMP (u-cAMP), fractional sodium excretion (FENa), free water
clearance (CH2O), as well as plasma concentrations of vasopressin (AVP), renin (PRC), angiotensin II (Ang II),
aldosterone (Aldo), and atrial and brain natriuretic peptide (ANP, BNP) in 21 patients with essential hypertension
and 20 normotensive controls during 24-h urine collection (baseline), and after hypertonic saline infusion on a 4-
day high sodium (HS) diet (300 mmol sodium/day) and a 4-day low sodium (LS) diet (30 mmol sodium/day).
Results: At baseline, no differences in u-AQP2CR or u-ENaCb-CR were measured between patients and controls. U-
AQP2CR increased significantly more after saline in patients than controls, whereas u-ENaCb-CR increased similarly.
The saline caused exaggerated natriuretic increases in patients during HS intake. Neither baseline levels of u-PGE2,
u-cAMP, AVP, PRC, Ang II, Aldo, ANP, and BNP nor changes after saline could explain the abnormal u-AQP2CR
response.
Conclusions: No differences were found in u-AQP2CR and u-ENaCb-CR between patients and controls at baseline.
However, in response to saline, u-AQP2CR was abnormally increased in patients, whereas the u-ENaCb-CR response
was normal. The mechanism behind the abnormal AQP2 regulation is not clarified, but it does not seem to be
AVP-dependent.
Clinicaltrial.gov identifier: NCT00345124.
Background
Dysregulation of the expression/shuttling of the renal
epithelial sodium channel (ENaC) and the aquaporin-2
water channel (AQP2) has been suggested to play a role
in the pathogenesis of essential hypertension.
ENaC is responsible for the reabsorption of sodium
through the apical membrane of the connecting tubule
and the collecting duct and plays a key role in control-
ling sodium balance, extracellular fluid volume, and
blood pressure. ENaC is a heteromultimeric protein
composed of three homologous subunits (a, b and g)
[1,2]. Aldosterone (Aldo) is the main hormonal regula-
tor of ENaC [3,4]. Binding of Aldo to the intracellular
mineralocorticoid receptor increases the transcription
and the apical translocation of ENaC [5,6]. ENaC is
excreted into the urine. Recently, our group demon-
strated a significant correlation between changes in the
urinary excretion of the ENaC b-subunit (u-ENaCb) and
changes in urinary sodium excretion [7]. Thus, u-ENaCb
has been suggested as a marker of the transport of
sodium via ENaC.
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principal cells. AVP is the main hormonal regulator of
AQP2 [8,9]. Binding of AVP to V2 receptors in the
basolateral membrane stimulates adenylate cyclase pro-
ducing cAMP and protein kinase A (PKA). Short-term
AVP exposure results in trafficking of subapical vesicles
containing AQP2 to the apical plasma membrane,
whereas long-term exposure causes a marked increase
in the AQP2 whole-cell abundance via regulation of
AQP2 gene transcription and AQP2 protein degradation
[9-12]. Withdrawal of AVP leads to retrieval of AQP2
from the apical plasma membrane into subapical vesicles
[11]. AQP2 is excreted into the urine [13-15] and is
used as a marker for the action of AVP on the collecting
ducts.
An increased expression of ENaC subunits and an
increased expression and apical targeting of AQP2 has
been reported in spontaneous hypertensive rats, an experi-
mental model of hypertension [16-18]. These results
adjoined with the existence of 1) an abnormal natriuresis
in essential hypertension, 2) an abnormal pressure-natriur-
esis relationship in essential hypertension, 3) a genetic
linkage between a monogenic form of human hyperten-
sion, Liddle’s syndrome, and ENaC [19], 4) a genetic link-
age between systolic blood pressure and ENaC subunits in
essential hypertension [20-22], and 5) an association of
ENaC polymorphisms and essential hypertension [23-25],
suggest that an abnormal regulation of the expression/
shuttling of AQP2 and/or ENaC could be involved in the
pathogenesis of essential hypertension.
In the present study, we wanted to test the hypothesis
that u-AQP2 and u-ENaC were abnormal in essential
hypertension during dietary high sodium (HS) intake
and/or during dietary low sodium (LS) intake, and that
these variables responded abnormally to a hypertonic
saline infusion.
In order to analyse the regulation of the expression/
shuttling of AQP2 and ENaC in essential hypertension,
we performed a randomised, cross-over trial with
patients with essential hypertension and normotensive
control subjects. We compared the absolute values of u-
AQP2 and u-ENaCb corrected for creatinine (u-AQP2CR
and u-ENaCb-CR), fractional sodium excretion (FENa),
free water clearance (CH2O), urinary excretion of prosta-
glandin E2 (u-PGE2), urinary excretion of cyclic-AMP
(u-cAMP), and plasma concentrations of AVP, renin
(PRC), angiotensin II (Ang II), Aldo, atrial natriuretic
peptide (ANP), and brain natriuretic peptide (BNP) in
patients with essential hypertension and normotensive
controls during both HS and LS intake. Furthermore,
we compared the relative changes in the above men-
tioned effect variables after a hypertonic saline infusion
during both diets.
Methods
Patients and control subjects
Patients
The inclusion criteria for patients with essential hyper-
tension were: 1) white men and women, 2) age between
18 and 65 years, 3) arterial hypertension, defined by 24-
h ambulatory blood pressure above 125 mmHg systolic
or 80 mmHg diastolic, and 4) body mass index (BMI) ≤
30 kg m
-2. The exclusion criteria were: 1) abnormal
renography, 2) a medical history or clinical signs of
heart, lung, liver, kidney, brain, endocrine organ, cardio-
vascular or neoplastic disease, 3) severe hypertension, 4)
abnormal biochemical screening of the blood regarding
haemoglobin, white blood cell count, platelets, sodium,
potassium, creatinine (> 200 μmol l
-1), albumin, biliru-
bin, alanine aminotransferase, alkaline phosphatase, cho-
lesterol, and glucose, 5) abnormal urine screening for
blood, albumin, and glucose, 6) abnormal electrocardio-
gram, 7) drug or alcohol abuse, 8) smoking, 9) preg-
nancy or breast feeding, 10) blood donation less than
one month before the examination, and 11) unwilling-
ness to use contraceptives if fertile woman (in order to
avoid to infuse potentially pregnant women with 51Cr-
EDTA and hypertonic saline). The withdrawal criteria
were: 1) lack of compliance, 2) withdrawal of consent,
and 3) development of one of the exclusion criteria dur-
ing the study. Antihypertensive agents were discontin-
ued two weeks before each study day. The blood
pressure of the subjects was controlled once a week in
the two week period. If blood pressures rose to levels
above 170 mmHg systolic or 105 mmHg diastolic, sub-
stitution treatment with metoprolol was initiated (this
did not happen in any of the patients).
Control subjects
The inclusion criteria for the normotensive controls
were: 1) white men and women, 2) age between 18 and
65 years, 3) 24-h ambulatory blood pressure below 125
mmHg systolic and 80 mmHg diastolic. The exclusion-
and withdrawal criteria w e r et h es a m ea sf o rt h e
patients. None of the normotensive controls received
any medication, except oral contraceptives.
Recruitment
The patients with essential hypertension were recruited
from the Nephrological out-patient clinic of the Depart-
ment of Medicine, Holstebro Hospital. The control sub-
jects were recruited by advertising in public institutions
and private companies.
Ethics and approvals
The study was approved by the local Medical Ethics
Committee (JRN RRS-2006-1014-(2733-06)). The study
was conducted in conformity with the principles of the
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were obtained from all the subjects. The study was
registered at the registration site: http://www.clinical-
trials.gov (NCT00345124).
Design
We performed two randomized, cross-over studies, one
with patients with essential hypertension and one with
normotensive controls. Each subject was studied on two
separate days at least three weeks apart. During four
days before the study day, the subjects consumed either
a HS or LS diet in randomized order. The results of the
patients are compared to the results of the normotensive
controls. Furthermore, in both patients and controls the
results obtained during HS and LS intake are compared.
Effect variables
The primary effect variable was u-AQP2CR, and the sec-
ondary effect variables were urinary sodium excretion
rate (UNa), FENa,u - E N a C b-CR, urine volume (V), CH20,
serum osmolality (s-osm), urine osmolality (u-osm), u-
cAMP and u-PGE2, plasma concentrations of AVP,
PRC, Ang II, Aldo, ANP, BNP, sodium (p-Na), and albu-
min (p-albumin), systolic and diastolic blood pressure,
heart rate, body weight, and glomerular filtration rate
(GFR).
Number of subjects
A difference in u-AQP2 of 0.25 ng min
-1 was considered
the minimal relevant difference based on interventions
in previous pilot experiments. A sample size of 20-21
subjects who could be evaluated had 90% power to
detect this difference assuming a level of significance of
5% and a standard deviation of 0.24 ng min
-1. Because a
few subjects were expected to drop out, 25 subjects
were included in each group.
Experimental procedure prior to the study day
Five days before the study day, the subjects collected a
standardized, HS (approx. 300 mmol sodium day
-1/17.5
gs a l td a y
-1) or LS (approx. 30 mmol sodium day
-1/1.8 g
salt day
-1), 4-day diet from the hospital kitchen.
Depending on the individually estimated energy require-
ment, the participants were given either a diet of 8,000
or 11,000 kJ day
-1. The energy distribution was: 55%
carbohydrates, 15% proteins, and 30% lipids. The 4-day
diet was started the following morning.
The fluid intake was also standardized during the four
days. The subjects were asked to drink exactly 250 ml
per 1000 kJ day
-1 and to abstain from coffee, tea, and
alcoholic beverages.
T h es u b j e c t sw e r ei n s t r u c ted to keep their physical
activity unchanged during the two experiments and to
abstain from hard training.
The subjects collected their urine for 24 hours the day
before the study day.
Experimental procedure on the study day
On the study day, the subjects were asked to drink 175
ml of water every 30 minutes from 7:00 AM. The sub-
jects arrived at the department at 8:00 AM. Peripheral
IV lines were inserted into the antecubital veins of both
forearms, one for infusion of 51Cr-EDTA and hyper-
tonic saline, and one for withdrawal of blood samples.
The subjects were kept in the supine position from 8:00
AM to 1:30 PM except during voiding, which took place
in the sitting or standing position.
At 8:30 AM, a priming dose of 51Cr-EDTA was admi-
nistered, followed by sustained infusion. After 60 min-
utes of equilibration, the study continued with five
clearance periods, the first t w oo f3 0m i n u t e sd u r a t i o n
(P1-P2), the last three of 60 minutes duration (P3-P5).
The first two clearance periods were baseline periods.
At 10:30 AM, 7 ml kg
-1 of 3% saline were given over
30 minutes.
Blood pressure and heart rate were measured every 30
minutes from 9:30 AM to 1:30 PM.
Urine was collected in each clearance period and ana-
lyzed for sodium, osmolality, u-AQP2, u-ENaCb,u -
cAMP, u-PGE2, and 51Cr-EDTA.
Blood samples were drawn every 30 minutes from 9:30
AM to 10:30 AM and every hour from 11:30 AM to
1:30 PM, and were analyzed for sodium, osmolality, and
51Cr-EDTA. In addition, analysis of AVP, PRC, Ang II,
Aldo, ANP and BNP were performed from blood sam-
ples drawn at 10:30 AM, 11:30 AM, 12:30 PM, and 1:30
PM.
Methods
All blood samples were centrifuged for 15 minutes at
3,000 rpm at 4°C. Plasma was separated from blood
cells and kept frozen at -20°C until assayed. ANP in
plasma was determined by radioimmunoassay (RIA), as
previously described [26]. ANP was extracted from
plasma with C18 September-Pack (Water Associates,
Milford, MA, USA) using ethanol, acetic acid, and
water. For RIA, rabbit anti-ANP antibody was obtained
from the Department of Clinical Chemistry, Bispebjerg
H o s p i t a l ,D e n m a r k .T h em i n i mal detection concentra-
tion was 0.5 pmol l
-1. The coefficients of variation were
12% (inter-assay) and 10% (intra-assay). BNP in plasma
was determined by RIA as previously described [27].
Immunoreactive BNP was extracted from plasma with
C18 September-Pack (Water Associates, Milford, MA,
USA) eluted by 80% ethanol in a 4% acetic acid solution.
A rabbit anti-BNP antibody without cross-reactivity with
urodilatin or a-ANP was developed in our lab. The
minimal detection concentration was 0.5 pmol l
-1.T h e
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(intra-assay). AVP in plasma was measured by RIA
using a modification of the method described previously
[28]. AVP was extracted from plasma with C18 Septem-
ber-Pack (Water Associates, Milford, MA, USA). The
antibody against AVP was a gift from Professor Jacques
Dürr, Miami, FL, USA. The minimal detection concen-
tration was 0.5 pmol l
-1. The coefficients of variation
were 13% (inter-assay) and 9% (intra-assay). Ang II in
plasma was determined by RIA using a modification
[29] of the method originally described [30]. Ang II was
extracted from plasma with C18 September-Pack (Water
Associates, Milford, MA, USA). The antibody against
Ang II was obtained from the Department of Clinical
Physiology, Glostrup Hospital, Denmark. The minimal
detection concentration was 2 pmol l
-1. The coefficients
of variation were 12% (inter-assay) and 8% (intra-assay).
Aldo was determined by RIA using a commercial kit
(Diagnostic Systems Laboratories Inc, Webster, TX,
USA). The minimal detection concentration was 22
pmol l
-1. The coefficients of variation were 8.2% (inter-
assay) and 3.9% (intra-assay). PRC was also determined
by a commercial RIA (CIS Bio International, Gif-sur-
Yvette Cedex, France). The minimal detection concen-
tration was 0.5 pg ml
-1. The coefficients of variation
were 14.5% (inter-assay) and 4.5% (intra-assay).
Urine samples were centrifuged for 5 minutes at 3,000
rpm, and 125-1000 μl of the supernatant was freeze
dried and kept frozen at -20°C for two to eight months
until assayed. We have done pilot experiments to ensure
that the concentration of the effect variables in the
urine does not decrease over time. The experiments
showed that the effect variables are stable at -20°C for
two years. U-AQP2 was measured by a RIA as pre-
viously described [31]. The anti-AQP2 antibody for RIA
was obtained from Søren Nielsen (The Water and Salt
Research Center, Institute of Anatomy, Aarhus Univer-
sity, Denmark). The antibody was raised in rabbits
against the 15 C-terminal amino-acids of human AQP2.
The minimal detection concentration was 32 pg tube
-1.
The coefficients of variation were 11.7% (inter-assay)
and 5.9% (intra-assay). U-ENaCb was measured by a
newly developed RIA [7,32]. ENaCb was synthesized and
purchased by Lofstrand Labs Limited (Gaithersburg,
MD, USA). The b-ENaC antibody was raised against a
synthetic peptide in rabbits. The lower detectable limit
of the assay was 34 pg tube
-1. The inter-assay variation
was 12% at a mean level of 78 pg tube
-1,a n d1 0 %a ta
mean level of 155 pg tube
-1. The intra-assay variation
was 6.4% and 9.0% at a mean level of 180 pg tube
-1 and
406 pg tube
-1, respectively. U-cAMP was measured by
RIA using a commercial kit (Biomedical Technologies
Inc., Stoughton, MA, USA). The minimal detection con-
centration was 0.05 pmol l
-1. The coefficients of
variation were 8% (inter-assay) and 3% (intra-assay). U-
PGE2 was measured by RIA using a commercial kit
(Assay Designs, Inc., Ann Arbor, MI, USA). The mini-
mal detection concentration was 8.26 pg ml
-1. The coef-
ficients of variation were 10.9% (inter-assay) and 6.3%
(intra-assay).
S-osm and u-osm were measured by freezing-point
depression (Advanced Model 3900 multisampling osm-
ometer). CH2O was determined according to the formula:
CH2O =V-C osm, where V is the urine output, and Cosm
is the osmolality clearance.
Urine was screened for blood, albumin, and glucose
with standard urine test strips. Plasma and urinary con-
centrations of sodium and creatinine were determined at
the Department of Clinical Biochemistry, Holstebro
Hospital, Denmark using conventional methods. All
clearances were standardized to a body surface area of
1.73 m
2. GFR was measured using the constant infusion
clearance technique with 51Cr-EDTA as reference.
24-h ambulatory blood pressure was measured with
BOSO TM-2450 (Kiwex, Denmark).
Clinic blood pressure was measured with UA-743 digi-
tal blood pressure meter (A&D Company, Tokyo,
Japan).
Statistics
Statistical analyses were performed using SPSS version
15 (SPSS Inc., Chicago, IL, USA). Single baseline values
were obtained by taking the weighted average of the
measurements from the two baseline periods. The base-
line values of the two groups were compared by Stu-
dent’s t-test. The baseline values during HS and LS
intake were compared by paired samples t-tests. We
used the “General Linear Model Repeated Measures”
procedure in SPSS with time as within-subject factor
and blood pressure as between-subject factor to com-
pare the effect of blood pressure. The changes in
response to the hypertonic saline infusion in each group
were analyzed with the “General Linear Model Repeated
Measures” procedure with time as within-subject factor
and paired samples t-tests with Bonferroni correction as
post hoc tests. P values < 0.05 were considered signifi-
cant. Variables are normally distributed and presented
as means with standard deviations (SD) or 95% confi-
dence intervals, if not otherwise stated.
Results
Demographics
Twenty five patients with essential hypertension and 25
normotensive controls were enrolled in the study. Four
patients were withdrawn from the study because they
withdrew their consent to participation. Five normoten-
sive controls were withdrawn from the study, two
because of failure to obtain intravenous access, and
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Table 1 shows the clinical and laboratory data of the 21
patients and 20 controls completing the study. The
patients with essential hypertension had significantly
higher systolic and diastolic blood pressure during both
day and night compared with the controls. No signifi-
cant difference in heart rate was found between patients
and controls. Of the 21 patients, 16 were dippers (noc-
turnal BP fall ≥ 10%) and 5 were non-dippers (nocturnal
BP fall < 10%). All the control subjects had a p-creati-
nine within the normal range (i.e. 50-90 μmol/l for
women and 60-105 μmol/l for men).
24-h urine collection
Table 2 shows the results of the 24-h urine collection in
the patients with essential hypertension and the normo-
tensive controls during HS and LS intake. U-AQP2CR
and u-ENaCb-CR were the same in patients and controls
in the 24-h urine. U-AQP2CR was significantly lower
during LS intake than HS intake in both patients and
controls, whereas u-ENaCb-CR was the same during LS
and HS. The only significant difference between patients
and controls was a significantly lower u-osm in the
patients during LS intake. UNa was significantly lower in
both patients and controls during LS intake compared
to during HS intake, indicating that both groups had
kept the supplied diets.
Hypertonic saline infusion
The effect variables are shown in Table 3 (UNa,F E Na
and u-ENaCb-CR), Table 4 (V, CH2O,u - A Q P 2 CR,u - o s m ,
u-c-AMP, u-PGE2, and s-osm), Table 5 (PRC, AngII,
A l d o ,A N P ,B N Pa n dA V P ) ,a n dT a b l e6( G F R ,S B P ,
DBP and HR) before (baseline), and after the hypertonic
saline infusions in the patients with essential hyperten-
sion and the normotensive controls during HS and LS
intake, respectively. The relative changes in the effect
variables are shown in Tables 7 and 8.
Baseline results
We found no difference in the above mentioned effect
parameters between patients and controls at baseline,
except lower Ang II in patients compared with controls
during HS intake (Table 5) and as expected higher sys-
tolic and diastolic blood pressure during HS intake com-
pared with LS intake in patients, but not in controls. LS
intake resulted in extracellular volume depletion in both
groups. Thus during LS intake, we found significantly
Table 1 Clinical and laboratory characteristics of 21
patients with essential hypertension and 20
normotensive controls
Patients Controls t-test
Men/women 14/7 12/8
Age (years) 55 (9) 48 (9) P = 0.102
BMI (kg m
-2) 25.6 (2.5) 24.2 (2.7) P = 0.160
p-sodium (mmol l
-1) 139.4 (2.1) 139.6 (2.2) P = 0.798
p-potassium (mmol l
-1) 3.9 (0.4) 3.9 (0.3) P = 0.992
p-creatinine (μmol l
-1) 74.9 (9.4) 72.9 (10.9) P = 0.532
24-h ambulatory
SBP (mmHg) 144 (11) 119 (6) P < 0.001
DBP (mmHg) 87 (7) 75 (4) P < 0.001
HR (beats min
-1) 71 (13) 68 (7) P = 0.503
Daytime ambulatory
SBP (mmHg) 148 (11) 124 (7) P < 0.001
DBP (mmHg) 90 (8) 78 (4) P < 0.001
HR (beats min
-1) 74 (13) 71 (7) P = 0.468
Nighttime ambulatory
SBP (mmHg) 126 (12) 104 (12) P < 0.001
DBP (mmHg) 76 (9) 63 (4) P < 0.001
HR 59 (10) 56 (9) P = 0.487
Values are means (SD). Student’s t-test.
Table 2 24-hours urine collection
t-test
UNa (μmol min
-1)
HS Patients 203 (179; 227)§ P = 0.215
Controls 226 (195; 257)§
LS Patients 42 (31; 53) P = 0.494
Controls 47 (35; 59)
u-EnaCb-CR (pg μmol
-1)
HS Patients 14.33 (12.30; 16.37) P = 0.980
Controls 14.37 (12.34; 16.40)
LS Patients 12.54 (11.35; 13.74) P = 0.084
Controls 14.19 (13.00; 15.38)
V (ml min
-1)
HS Patients 2702 (2331; 3074) P = 0.628
Controls 2828 (2442; 3213)
LS Patients 2991 (2721; 3260) P = 0.207
Controls 2715 (2353; 3078)
u-AQP2CR (ng mmol
-1)
HS Patients 143 (117; 168)§ P = 0.781
Controls 147 (129; 165)§
LS Patients 101 (89; 114) P = 0.192
Controls 112 (101; 122)
u-osm (mOsm kg
-1)
HS Patients 405 (363; 447)§ P = 0.409
Controls 436 (372; 499)§
LS Patients 221 (204; 238) P = 0.026
Controls 306 (231; 381)
Values are means with 95% confidence intervals in brackets. UNa, urinary
sodium excretion rate; u-ENaCb-CR, urinary ENaCb excretion corrected for
creatinine; V, urinary flow; u-AQP2CR, urinary AQP2 excretion corrected for
creatinine; u-osm, urine osmolality; t-test: patients compared with controls,
Student’s t-test. § P < 0.001, HS vs. LS intake, paired samples t-test.
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osm, and s-osm (Table 4), significantly lower ANP and
BNP, and significantly higher PRC, ANG II and Aldo
(Table 5), and significantly lower GFR (Table 6) at base-
line in both groups. Moreover, u-AQP2CR was signifi-
cantly lower and u-PGE2 significantly higher during LS
intake compared with during HS intake in both patients
and controls (Table 4).
U-ENaCb-CR and u-cAMP were significantly lower
during LS intake compared with HS intake in the
patients at baseline, but the differences were very small.
U-ENaCb-CR and u-cAMP were the same in the control
group at baseline (Table 3 and 4).
Systolic blood pressure was significantly lower during
LS intake than HS intake at baseline in the patient
group, but not in the control group (Table 6).
Sodium excretion and u-ENaCb-CR
The hypertonic saline infusion was accompanied by sig-
nificant increases in UNa and FENa in both patients and
controls during both HS and LS intake. The increases
lasted throughout the experiment (Table 3). During HS
intake, the relative increases in both UNa and FENa were
significantly higher in the patients with essential hyper-
tension than in the controls 120 minutes after infusion
start (Table 7). The relative increases in UNa and FENa
were significantly higher during LS intake compared
with HS intake throughout the experiment in both
groups (Table 7).
A significant increase was seen in u-ENaCb-CR in
patients with essential hypertension during LS intake
and in the normotensive controls during both HS and
LS intake 120 minutes after the saline infusion start
(Table 3). There was no difference between patients
and controls with regard to the relative increases
(Table 7).
Water excretion, u-AQP2CR, u-osm, u-cAMP, u-PGE2, and s-
osm
In both patients and controls, the hypertonic saline infu-
sion induced a significant and sustained decrease in V
(Table 4). The relative decreases in V did not differ
between patients and controls (Table 8).
CH2O decreased significantly after the hypertonic sal-
ine infusion in both groups and during both diets with a
maximum after 120 minutes (Table 4). CH2O changed
from positive values at baseline to negative values after
infusion, indicating a change from water excretion to
water reabsorption. The relative decreases in CH2O did
not differ between patients and controls. In the patients
with essential hypertensiont h er e l a t i v ec h a n g e sw e r e
significantly higher during HS intake than during LS
intake throughout the experiment. In the normotensive
controls, this was only the case 60 minutes after infu-
sion start (Table 8).
U-AQP2CR increased significantly in response to the
hypertonic saline infusion in both patients and controls
during both diets (Table 4). The increase reached maxi-
mum 120 minutes after the infusion start. The relative
increases were significantly higher in the patients than
in the controls throughout the experiment (HS: 35 ver-
sus 6%; LS: 46 versus -1%) (Table 8).
Table 3 Effects of hypertonic saline infusion (3%, 7 ml kg
-1)o nU Na,F E Na, u-ENaC and b-CR in 21 patients with essential
hypertension and 20 normotensive controls during high and low sodium intake
Baseline 60 Min 120 Min 180 Min PGLM RM
UNa (μmol min
-1)
HS Patients 343 (300; 386)§ 615 (499; 731)† 700 (581; 819)† 541 (471; 611)† P = 0.110
Controls 323 (285; 361)§ 497 (321; 672)† 499 (357; 642)† 460 (366; 554)†
LS Patients 91 (57; 125) 254 (168; 340)† 275 (192; 357)† 277 (211; 343)† P = 0.164
Controls 57 (40; 74) 175 (62; 288)† 191 (99; 282)† 181 (123; 239)†
FENa (%)
HS Patients 2.66 (2.34; 2.98)§ 5.10 (4.20; 6.00)† 5.35 (4.46; 6.24)† 4.57 (3.96; 5.19)† P = 0.030
Controls 2.51 (2.10; 2.92)§ 3.73 (2.61; 4.86)† 3.72 (2.76; 4.68)† 3.49 (2.85; 4.14)†
LS Patients 0.75 (0.49; 1.01) 2.24 (1.55; 2.93)† 2.29 (1.69; 2.90)† 2.28 (1.84; 2.72)† P = 0.059
Controls 0.49 (0.34; 0.65) 1.34 (0.67; 2.01)† 1.52 (0.90; 2.15)† 1.44 (1.06; 1.82)†
u-EnaCb-CR (pg μmol
-1)
HS Patients 11.4 (10.2; 12.7)§ 10.4 (9.4; 11.3) 10.8 (9.6; 12.1) 11.1 (9.6; 12.6) P = 0.796
Controls 11.2 (9.9; 12.5) 10.8 (9.7; 12.0) 12.2 (10.7; 13.8)† 11.0 (9.4; 12.6)
LS Patients 10.4 (9.4; 11.3) 10.7 (9.3; 12.2) 11.5 (10.4; 12.6)† 10.9 (10.0; 11.9) P = 0.716
Controls 11.5 (9.8; 13.2) 11.2 (10.0; 12.4) 12.4 (11.3; 13.6)† 11.9 (10.2; 13.5)
Values are means with 95% confidence intervals in brackets. UNa, urinary sodium excretion rate; FENa, fractional sodium excretion; u-ENaCb-CR, urinary ENaCb
excretion corrected for creatinine. PGLM RM: patients compared with controls, GLM repeated measures with time as within-subject factor and blood pressure as
between-subject factor. * P < 0.05, baseline patients vs. controls, Student’s t-test. § P < 0.05, baseline HS vs. LS, paired samples t-test. † P < 0.05, compared with
baseline, paired samples t-test
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Page 6 of 15U-osm increased significantly in response to the
hypertonic saline infusion in both patients and controls
during both diets (Table 4). The increases lasted
throughout the experiment with a maximum 120 min-
utes after infusion start. The relative increases did not
differ between patients and controls, but they were sig-
nificantly higher during LS intake in both groups
(Table 8).
U-cAMP decreased in response to the saline infusion
in both patients and controls (Table 4). In the control
subjects the decrease was not significant during HS
intake, but there was no difference in the relative
decrease between patients and controls during any of
the diets (Table 8).
U-PGE2 decreased in response to the saline infusion in
both patients and controls during both diets (Table 4)
Table 4 Effects of hypertonic saline infusion (3%, 7 ml kg
-1)o nV ,C H2O, u-AQP2CR, u-osm, u-cAMP, u-PGE2, and s-osm
in 21 patients with essential hypertension and 20 normotensive controls during high and low sodium intake
Baseline 60 Min 120 Min 180 Min PGLM RM
V (ml min
-1)
HS Patients 8.7 (7.7; 9.6)§ 5.0 (4.0; 6.0)† 4.1 (3.3; 4.8)† 3.3 (2.8; 3.8)† P = 0.076
Controls 8.1 (7.4; 8.7)§ 4.1 (3.1; 5.0)† 2.9 (2.2; 3.6)† 3.3 (2.6; 4.0)†
LS Patients 7.4 (6.6; 8.2) 4.0 (2.6; 5.4)† 2.8 (1.6; 4.1)† 2.8 (2.1; 3.4)† P = 0.078
Controls 6.6 (5.9; 7.2) 2.7 (1.9; 3.5)† 1.8 (1.1; 2.4)† 2.3 (1.7; 2.9)†
CH2O (ml min
-1)
HS Patients 4.1 (3.1; 5.0) -0.6 (-1.2; 0.0)† -2.3 (-2.8; -1.9)† -1.9 (-2.3; -1.5)† P = 0.495
Controls 3.5 (2.7; 4.3) -1.0 (-1.4; -0.5)† -2.2 (-2.7; -1.7)† -1.6 (-2.2; -1.1)†
LS Patients 4.6 (4.0; 5.3) 0.9 (-0.2; 1.9)† -0.6 (-1.6; 0.5)† -0.7 (-1.4; 0.0)† P = 0.216
Controls 4.0 (3.3; 4.7) 0.1 (-0.2; 0.4)† -0.9 (-1.3; -0.5)† -0.6 (-1.0; -0.1)†
u-AQP2CR (ng mmol
-1)
HS Patients 154 (137; 172)§ 206 (179; 233)† 220 (196; 243)† 201 (179; 222)† P = 0.055
Controls 156 (140; 172)§ 162 (146; 177) 186 (155; 217)† 175 (151; 199)†
LS Patients 109 (87; 130) 136 (120; 153)† 140 (125; 155)† 135 (125; 145)† P = 0.589
Controls 118 (107; 130) 120 (94; 147) 129 (105; 153) 122 (105; 139)
u-osm (mOsm kg
-1)
HS Patients 169 (130; 209)§ 345 (311; 379)† 484 (445; 522)† 479 (431; 526)† P = 0.237
Controls 172 (149; 194)§ 371 (329; 413)† 542 (485; 599)† 486 (411; 562)†
LS Patients 111 (98; 124) 263 (221; 305)† 433 (368; 497)† 405 (343; 467)† P = 0.231
Controls 121 (101; 141) 271 (240; 303)† 497 (413; 581)† 438 (348; 529)†
u-cAMP (nmol min
-1)
HS Patients 7.10 (6.04; 8.16)§ 6.26 (5.58; 6.94) 5.87 (5.16; 6.58)† 5.62 (4.91; 6.33)† P = 0.388
Controls 5.87 (4.95; 6.79) 6.02 (5.16; 6.87) 5.41 (4.73; 6.09) 5.34 (4.67; 6.02)
LS Patients 6.34 (5.39; 7.30) 5.91 (5.24; 6.57) 5.19 (4.51; 5.87)† 5.25 (4.55; 5.95)† P = 0.240
Controls 5.64 (4.58; 6.70) 4.91 (3.87; 5.95)† 4.30 (3.61; 4.99)† 4.67 (3.93; 5.40)†
u-PGE2 (μmol min
-1)
HS Patients 1095 (862; 1329)§ 980 (383; 1577) 754 (590; 917)† 499 (418; 581)† P = 0.772
Controls 1180 (843; 1516)§ 868 (681; 1055)† 752 (559; 945)† 653 (454; 851)†
LS Patients 2294 (1103; 3485) 1276 (864; 1687)† 648 (490; 806)† 679 (549; 809)† P = 0.505
Controls 1487 (1049; 1926) 1072 (850; 1295)† 736 (536; 935)† 810 (602; 1018)†
s-osm (mOsm kg
-1)
HS Patients 290 (289; 292)§ 297 (296; 299)† 294 (292; 295)† 290 (289; 292) P = 0.263
Controls 290 (289; 291)§ 296 (295; 297)† 292 (291; 293)† 290 (288; 291)
LS Patients 286 (283; 289) 294 (292; 296)† 292 (290; 294)† 289 (287; 291)† P = 0.734
Controls 286 (285; 288) 293 (292; 295)† 291 (289; 292)† 288 (287; 290)†
Values are means with 95% confidence intervals in brackets. V, urinary flow; CH2O, free water clearance; u-AQP2CR, urinary AQP2 excretion corrected for creatinine;
u-osm, urine osmolality; u-cAMP, urinary cAMP excretion; and u-PGE2, urinary prostaglandin E2 excretion; and s-osm, serum osmolality. PGLM RM: patients
compared with controls, GLM repeated measures with time as within-subject factor and blood pressure as between-subject factor. * P < 0.05, baseline patients
vs. controls, Student’s t-test. § P < 0.05, baseline HS vs. LS, paired samples t-test. † P < 0.05, compared with baseline, paired samples t-test
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Page 7 of 15with a nadir 180 minutes after infusion start during HS
intake and one hour earlier during LS intake. The rela-
tive decreases in u-PGE2 were not significantly different
between patients and controls or between the two diets
(Table 8).
S-osm increased significantly in both patients and
controls during both diets with a maximum 60 min-
utes after infusion start. The maximal increase did not
differ between patients and controls or between HS
and LS intake (Table 8), but only during HS intake
baseline levels were reached 180 minutes after infusion
start.
Vasoactive hormones
In the patients, PRC decreased 60 minutes after infusion
start during HS intake and one hour later during LS
intake. PRC did also decrease in the normotensive con-
trols, but the changes from baseline were only signifi-
cant during LS intake (Table 5). The relative decreases
in PRC did not differ between patients and controls or
between HS and LS intake (Table 9).
In both patients and controls, Ang II decreased sig-
nificantly in response to the hypertonic saline infusion
during LS intake, but not during HS intake (Table 5).
Accordingly, the relative decreases in Ang II were
Table 5 Effects of hypertonic saline infusion (3%, 7 ml kg
-1) on PRC, Ang II, Aldo, ANP, BNP, and AVP in 21 patients
with essential hypertension and 20 normotensive controls during high and low sodium intake
Baseline 60 Min 120 Min 180 Min PGLM RM
PRC (mU l
-1)
HS Patients 4.8 (2.9; 6.7)§ 3.8 (2.5; 5.1)† 3.5 (2.0; 5.1) 4.2 (2.1; 6.3) P = 0.311
Controls 6.5 (3.1; 9.8)§ 4.4 (3.0; 5.7) 4.8 (2.4; 7.2) 5.5 (2.5; 8.6)
LS Patients 13.6 (8.5; 18.8) 8.9 (5.8; 12.0) 6.6 (4.7; 8.4)† 8.2 (4.8; 11.6) P = 0.145
Controls 19.8 (13.5; 26.0) 11.1 (8.2; 14.0)† 11.5 (4.7; 18.3) 11.2 (4.5; 17.8)
AngII (pmol l
-1)
HS Patients 4.0 (3.2; 4.7)*§ 3.4 (2.3; 4.5) 3.5 (2.3; 4.7) 3.4 (2.4; 4.3) P = 0.079
Controls 6.1 (4.4; 7.8)§ 4.6 (2.8; 6.4) 4.4 (3.4; 5.4) 4.2 (3.1; 5.2)
LS Patients 11.7 (7.3; 16.0) 6.4 (4.5; 8.3)† 5.6 (4.5; 6.7)† 5.7 (4.1; 7.3)† P = 0.080
Controls 14.4 (11.1; 17.6) 9.3 (5.6; 12.9)† 8.8 (6.2; 11.3)† 7.7 (5.8; 9.6)†
Aldo (pmol l
-1)
HS Patients 227 (192; 261)§ 173 (147; 199)† 168 (144; 192)† 175 (152; 199)† P = 0.063
Controls 188 (154; 221)§ 145 (123; 166)† 137 (120; 155)† 151 (131; 170)
LS Patients 352 (275; 428) 237 (196; 279)† 214 (185; 244)† 231 (202; 260)† P = 0.973
Controls 365 (296; 434) 238 (193; 284)† 211 (178; 244)† 216 (188; 245)†
ANP (pmol l
-1)
HS Patients 11.7 (9.6; 13.9)§ 16.3 (12.5; 20.1) 14.4 (11.5; 17.4)† 12.8 (10.2; 15.4)† P = 0.415
Controls 11.1 (9.5; 12.7)§ 14.4 (12.1; 16.7) 12.9 (11.1; 14.8)† 11.6 (9.9; 13.3)†
LS Patients 7.4 (5.9; 8.8) 11.1 (8.6; 13.7)† 10.1 (7.8; 12.4)† 9.1 (7.2; 11.0)† P = 0.707
Controls 7.3 (5.8; 8.8) 10.4 (8.7; 12.0)† 9.5 (7.9; 11.0)† 8.9 (7.3; 10.4)†
BNP (pmol l
-1)
HS Patients 2.2 (0.8; 3.7)§ 2.6 (0.9; 4.2) 2.4 (1.1; 3.8)† 2.5 (1.1; 3.8) P = 0.938
Controls 2.2 (0.5; 3.9)§ 2.5 (0.6; 4.4) 2.6 (0.5; 4.7) 2.7 (0.5; 4.9)
LS Patients 0.9 (0.6; 1.2) 1.0 (0.6; 1.4) 1.1 (0.7; 1.4) 1.1 (0.7; 1.5) P = 0.941
Controls 1.0 (0.4; 1.5) 1.0 (0.5; 1.6) 1.1 (0.5; 1.7) 1.1 (0.5; 1.7)†
AVP (pg ml
-1)
HS Patients 0.69 (0.60; 0.77) 1.08 (0.91; 1.24)† 0.87 (0.75; 0.99)† 0.70 (0.60; 0.79) P = 0.520
Controls 0.66 (0.57; 0.75) 0.97 (0.82; 1.12)† 0.79 (0.66; 0.92)† 0.72 (0.60; 0.83)
LS Patients 0.65 (0.57; 0.73) 1.04 (0.88; 1.19)† 0.86 (0.75; 0.96)† 0.73 (0.64; 0.83) P = 0.535
Controls 0.66 (0.57; 0.75) 0.93 (0.75; 1.11)† 0.78 (0.66; 0.90)† 0.73 (0.56; 0.89)
Values are means with 95% confidence intervals in brackets. PRC, plasma renin concentration; Ang II, angiotensin II, Aldo, aldosterone; ANP, atrial natriuretic
peptide; and BNP, brain natriuretic peptide before (baseline) and 60, 120, and 180 minutes after a hypertonic saline infusion. PGLM RM: patients compared with
controls, GLM repeated measures with time as within-subject factor and blood pressure as between-subject factor. * P < 0.05, baseline patients vs. controls,
Student’s t-test. § P < 0.05, baseline HS vs. LS, paired samples t-test. † P < 0.05, compared with baseline, paired samples t-test
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Page 8 of 15Table 6 Effects of hypertonic saline infusion (3%, 7 ml kg
-1) on GFR, blood pressure, and heart rate in 21 patients with
essential hypertension and 20 normotensive controls during high and low sodium intake
Baseline 60 Min 120 Min 180 Min PGLM RM
Glomerular filtration rate (ml min
-1)
HS Patients 93 (87; 100)§ 85 (78; 91) 93 (85; 101) 86 (79; 93) P = 0.321
Controls 96 (88; 104)§ 90 (82; 98) 94 (86; 102) 93 (88; 99)
LS Patients 86 (81; 90) 78 (73; 84)† 84 (75; 93) 86 (77; 94) P = 0.458
Controls 89 (80; 98) 81 (72; 90) 83 (72; 94) 91 (81; 101)
Systolic blood pressure (mmHg)
HS Patients 142 (134; 150)*§ 148 (141; 155)† 145 (138; 151) 149 (141; 157)† P < 0.001
Controls 116 (110; 121) 119 (113; 125) 117 (111; 123) 119 (112; 125)
LS Patients 135 (129; 141)* 139 (133; 145) 138 (132; 145) 136 (130; 142) P < 0.001
Controls 114 (110; 118) 116 (110; 121) 115 (110; 120) 118 (112; 124)
Diastolic blood pressure (mmHg)
HS Patients 86 (81; 91)* 87 (81; 92) 87 (82; 92) 89 (83; 94) P < 0.001
Controls 70 (66; 73) 70 (66; 74) 70 (66; 74) 72 (69; 76)†
LS Patients 84 (80; 88)* 83 (78; 88) 84 (79; 89) 85 (80; 89) P < 0.001
Controls 69 (66; 72) 68 (65; 71) 67 (64; 71) 70 (67; 73)
Heart rate (beats min
-1)
HS Patients 56 (52; 60) 57 (53; 62) 58 (53; 63) 57 (54; 61) P = 0.204
Controls 52 (47; 57) 53 (49; 57) 54 (50; 59)† 54 (50; 59)
LS Patients 57 (53; 61) 59 (54; 63) 59 (55; 63) 59 (55; 62) P = 0.261
Controls 53 (49; 57) 56 (51; 60)† 57 (52; 61)† 56 (52; 60)†
Values are means (95% confidence intervals). PGLM RM: patients compared with controls, GLM repeated measures with time as within-subject factor and blood
pressure as between-subject factor. * P < 0.05, baseline patients vs. controls, Student’s t-test. § P < 0.05, baseline HS vs. LS, paired samples t-test. † P < 0.05,
compared with baseline, paired samples t-test
Table 7 Relative changes from baseline in UNa,F E Na, and u-ENaCb-CR in response to a hypertonic saline infusion (3%, 7
ml kg
-1) in 21 patients with essential hypertension and 20 normotensive controls during HS and LS intake
60 Min 120 Min 180 Min PGLM RM
ΔUNa (%)
HS Patients 87.4 (49.5; 125.4)§ 112.4 (72.0; 152.8)*§ 64.6 (41.4; 87.7)§ P = 0.122
Controls 48.2 (7.8; 88.6)§ 54.6 (18.4; 90.8)§ 44.0 (20.2; 67.9)§
LS Patients 388.9 (108.6; 669.2) 475.2 (133.8; 816.6) 513.7 (145.9; 881.5) P = 0.363
Controls 241.3 (92.9; 389.7) 306.8 (109.3; 504.3) 379.0 (168.4; 589.5)
ΔFENa (%)
HS Patients 96.6 (63.2; 130.1)§ 107.4 (72.8; 142.1)*§ 75.8 (56.2; 95.4)§ P = 0.047
Controls 50.6 (14.0; 87.1)§ 54.1 (21.0; 87.3)§ 46.2 (20.6; 71.7)§
LS Patients 379.9 (145.4; 614.4) 442.9 (142.6; 743.2) 486.0 (166.5; 805.5) P = 0.323
Controls 238.7 (106.8; 370.6) 286.5 (120.0; 453.0) 365.3 (157.5; 573.1)
Δu-ENaCb-CR (%)
HS Patients -5.2 (-15.7; 5.2) -4.1 (-12.7; 3.8) -3.5 (-12.0; 5.1) P = 0.311
Controls -1.7 (-9.6; 6.1) 8.3 (-7.6; 23.9) -1.8 (-10.8; 7.2)
LS Patients 5.2 (-5.7; 16.2) 13.9 (5.0; 22.7) 7.9 (-0.2; 16.0) P = 0.525
Controls -1.5 (-16.3; 13.2) 8.1 (-12.3; 28.5) 7.0 (-7.3; 21.3)
UNa, urinary sodium excretion rate; FENa, fractional sodium excretion; u-ENaCb-CR, urinary ENaCb excretion corrected for creatinine. Values are means (95%
confidence intervals). PGLM RM: HS compared with LS, GLM Repeated Measures with time as within-subject factor and blood pressure as between-subject factor. *
P < 0.05, patients vs. controls, Students t-test. § P < 0.05, HS compared with LS, paired samples t-test
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Page 9 of 15significantly larger during LS intake in both groups
(Table 9).
Aldo decreased significantly in both groups during
both diets. The decrease had a maximum 120 minutes
after the saline infusion start and lasted throughout
t h es t u d yd a y( T a b l e5 ) .T h er e l a t i v ed e c r e a s e sw e r e
not different between patients and controls, but were
significantly higher during LS intake in both groups
(Table 9).
The hypertonic saline infusion induced a significant
and sustained increase in ANP in both groups on both
study days (Table 5). The relative increases in ANP
were higher during LS intake than during HS intake
(Table 9).
Table 8 Relative changes from baseline in V, CH2O, u-AQP2CR, u-osm, u-cAMP, u-PGE2, and s-osm in response to a
hypertonic saline infusion (3%, 7 ml kg
-1) in 21 patients with essential hypertension and 20 normotensive controls
during HS and LS intake
60 Min 120 Min 180 Min PGLM RM
ΔV (%)
HS Patients -37.9 (-52.8; -23.0) -48.8 (-61.7; -35.9) -57.9 (-67.4; -48.3) P = 0.212
Controls -50.1 (-60.4; -39.8) -63.5 (-71.3; -55.7)§ -58.9 (-67.3; -50.4)
LS Patients -43.6 (-62.7; -24.6) -60.5 (-77.9; -43.0) -59.9 (-70.2; -49.6) P = 0.487
Controls -55.9 (-69.2; -42.6) -70.6 (-82.0; -59.3) -62.4 (-74.4; -50.4)
ΔCH2O (%)
HS Patients -111.0 (-130.7; -91.3)§ -152.7 (-174.3; -131.1)§ -142.5 (-158.4; -126.6)§ P = 0.715
Controls -130.3 (-161.7; -100.0)§ -164.7 (-227.2; -102.1) -141.5 (-238.4; -44.5)
LS Patients -78.5 (-102.0; -55.0) -112.1 (-135.8; -88.3) -113.4 (-128.0; -98.8) P = 0.519
Controls -90.9 (-103.7; -78.1) -121.8 (-131.3; -112.2) -112.5 (-125.5; -99.5)
Δu-AQP2CR (%)
HS Patients 35.0 (23.2; 46.7)* 46.2 (30.5; 61.9)* 31.9 (22.1; 41.7)* P = 0.005
Controls 6.1 (-4.5; 16.8) 22.2 (7.1; 37.4)§ 12.6 (1.5; 23.8)
LS Patients 45.9 (10.0; 81.9)* 50.1 (17.0; 83.1)* 41.2 (15.8; 66.6)* P = 0.019
Controls -1.1 (-13.5; 11.3) 6.7 (-6.2; 19.6) 3.0 (-5.5; 11.6)
Δu-osm (%)
HS Patients 134.7 (88.4; 181.0) 232.7 (168.4; 297.1)§ 228.6 (164.1; 293.1)§ P = 0.757
Controls 125.5 (97.1; 153.9) 235.5 (179.0; 292.0)§ 197.6 (142.1; 253.1)§
LS Patients 146.6 (103.6; 189.7) 315.3 (232.1; 398.5) 287.6 (211.8; 363.4) P = 0.661
Controls 141.6 (103.2; 180.0) 362.0 (252.9; 471.1) 297.4 (206.2; 388.6)
Δu-cAMP (%)
HS Patients -6.4 (-18.7; 5.9) -12.9 (-21.6; -4.1) -16.4 (-25.6; -7.3) P = 0.178
Controls 5.9 (-7.2; 19.0) -10.7 (-23.8; 2.5)§ -6.4 (-14.3; 1.4)
LS Patients -3.0 (-12.3; 6.3) -12.5 (-25.6; 0.6) -13.6 (-22.8; -4.4) P = 0.256
Controls -13.0 (-27.9; 2.0) -28.6 (-44.7; -12.6) -13.9 (-26.2; -1.7)
Δu-PGE2 (%)
HS Patients 11.1 (-70.9; 93.1) -20.8 (-39.4; -2.1) -46.3 (-56.4; -36.1) P = 0.410
Controls -22.0 (-33.2; -10.8) -34.6 (-44.3; -24.9) -43.4 (-50.6; -36.3)
LS Patients -9.4 (-38.2; 19.3) -38.0 (-63.4; -12.6) -40.9 (-59.3; -22.4) P = 0.689
Controls -16.1 (-34.4; 2.1) -45.0 (-56.3; -33.7) -41.6 (-51.1; -32.2)
Δs-osm (%)
HS Patients 2.4 (2.0; 2.9) 1.2 (0.8; 1.6)§ 0.0 (-0.4; 0.3)§ P = 0.671
Controls 2.2 (1.9; 2.5) 0.9 (0.6; 1.2)§ 0.1 (-0.3; 0.6)§
LS Patients 2.7 (2.3; 3.1) 2.0 (1.5; 2.5) 0.9 (0.4; 1.4) P = 0.215
Controls 2.5 (2.2; 2.8) 1.6 (1.2; 1.9) 0.7 (0.4; 1.0)
V, urinary flow; CH2O, free water clearance; u-AQP2CR, urinary AQP2 excretion corrected for creatinine; u-osm, urinary osmolality; u-c-AMP, urinary cyclic-AMP
excretion; u-PGE2, urinary prostaglandin E2 excretion; s-osm, serum osmolality. Values are means (95% confidence intervals). PGLM RM: HS compared with LS, GLM
Repeated Measures with time as within-subject factor and blood pressure as between-subject factor. * P < 0.05, patients vs. controls, Students t-test. § P < 0.05,
HS compared with LS, paired samples t-test
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Page 10 of 15In the patients, BNP increased significantly 120 min-
utes after infusion start during HS intake, while BNP
increased significantly 180 minutes after infusion start
during LS intake in the controls. The relative increases
did not differ between patients and controls or during
HS and LS intake (Table 9).
AVP increased significantly after the saline infusion in
both patients and controls during both diets (Table 5).
The increases followed the same pattern in patients and
controls with a maximum after 60 minutes (Table 5).
The relative changes in AVP were not significantly dif-
ferent between patient and controls or between HS and
LS intake throughout the study day (Table 9).
Blood pressure, heart rate, body weight, p-Na, and p-
albumin
The systolic blood pressure increased significantly in
response to the hypertonic saline during HS intake in
the patients, but not in the controls (Table 6).
The hypertonic saline did not affect the diastolic blood
pressure of the patients (Table 6). In the control group a
significant increase in the diastolic blood pressure was
seen 180 minutes after the saline infusion during HS
intake (Table 6).
The heart rate of the patients did not increase signifi-
c a n t l yi nr e s p o n s et ot h eh y p e r t o n i cs a l i n ei n f u s i o n ,
while the heart rate of the controls increased
Table 9 Relative changes from baseline in PRC, Ang II, Aldo, ANP, BNP, and AVP in response to a hypertonic saline
infusion (3%, 7 ml kg
-1) in 21 patients with essential hypertension and 20 normotensive controls during HS and LS
intake
60 Min 120 Min 180 Min PGLM RM
ΔPRC (%)
HS Patients -16.1 (-24.5; -7.7) -16.3 (-37.4; 4.8) -14.9 (-25.9; -3.9) P = 0.487
Controls -9.2 (-29.4; 11.0) -5.1 (-39.8; 29.5) -7.4 (-40.4; 25.7)
LS Patients -21.4 (-35.9; -6.8) -35.2 (-53.7; -16.6) -29.3 (-50.6; -8.0) P = 0.526
Controls -30.2 (-49.4; -10.9) -36.1 (-55.2; -16.9) -39.0 (-57.8; -20.3)
ΔAngII (%)
HS Patients -16.4 (-30.3; -2.6) -12.0 (-30.4; 6.4)§ -15.4 (-27.3; -3.5)§ P = 0.366
Controls -25.0 (-37.2; -12.8) -14.3 (-33.1; 4.4) -26.2 (-36.6; -15.8)§
LS Patients -33.5 (-48.0; -18.9) -34.7 (-50.1; -19.3) -38.5 (-50.7; -26.2) P = 0.845
Controls -36.8 (-48.1; -25.4) -32.3 (-56.4; -8.2) -45.1 (-52.3; -37.8)
ΔAldo (%)
HS Patients -21.7 (-28.7; -14.8)§ -24.3 (-30.6; -18.0)§ -20.1 (-26.5; -13.7) P = 0.654
Controls -21.5 (-27.0; -15.9)§ -23.7 (-31.8; -15.6)§ -14.9 (-25.9; -4.0)§
LS Patients -30.2 (-35.1; -25.4) -34.8 (-40.8; -28.8) -27.5 (-36.3; -18.7) P = 0.128
Controls -33.5 (-38.0; -28.9) -39.2 (-45.5; -32.9) -36.8 (-43.9; -29.6)
ΔANP (%)
HS Patients 38.6 (24.3; 53.0) 25.6 (13.2; 38.0) 10.9 (-1.0; 22.7)§ P = 0.319
Controls 30.6 (16.3; 45.0)§ 17.8 (8.3; 27.4)§ 6.2 (-3.6; 16.1)§
LS Patients 60.3 (30.9; 89.7) 48.3 (18.5; 78.1) 28.2 (11.3; 45.1) P = 0.481
Controls 48.9 (33.4; 64.4) 35.0 (22.6; 47.4) 25.8 (15.5; 36.1)
ΔBNP (%)
HS Patients 34.6 (-13.9; 83.1) 15.6 (9.4; 21.8) 22.0 (12.3; 31.8) P = 0.903
Controls 15.7 (0.8; 30.6) 22.0 (6.6; 37.4) 26.3 (7.1; 45.6)
LS Patients 15.7 (0.8; 30.6) 22.0 (6.6; 37.4) 26.3 (7.1; 45.6) P = 0.305
Controls 7.8 (0.9; 14.6) 14.9 (4.3; 25.6) 15.2 (5.1; 25.3)
ΔAVP (%)
HS Patients 57.5 (40.9; 74.1) 28.3 (15.9; 40.6) 3.2 (-5.7; 12.1) P = 0.666
Controls 50.9 (31.8; 69.9) 19.0 (6.7; 31.2) 8.4 (-0.7; 17.5)
LS Patients 64.4 (38.6; 90.2) 36.1 (20.5; 51.6) 15.3 (4.5; 26.2) P = 0.110
Controls 41.5 (23.0; 59.9) 20.6 (8.1; 33.1) 9.7 (-4.9; 24.4)
PRC, plasma renin concentration; Ang II, angiotensin II, Aldo, aldosterone; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; AVP, vasopressin. Values
are means (95% confidence intervals). PGLM RM: HS compared with LS, GLM Repeated Measures with time as within-subject factor and blood pressure as
between-subject factor. * P < 0.05, patients vs. controls, Students t-test. § P < 0.05, HS compared with LS, paired samples t-test
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Page 11 of 15significantly during both diets (Table 6). The relative
increases in heart rate did not differ between patients
and controls.
The body weight of the patients remained constant
throughout the study day during HS intake (80.4 kg (SD
12.5)), while it increased from 79.3 kg (SD 12.3) to 79.9
kg (SD 12.3) during LS intake. The increase was statisti-
cally significant (0.6 kg (SD 0.5), P < 0.001). The body
weight of the control subjects increased significantly
during both diets (HS: from 75.2 kg (SD 14.3) to 75.5 kg
(SD 14.3), P = 0.007; LS: from 74.4 kg (SD 14.1) to 75.1
k g( S D1 4 . 2 ) ,P<0 . 0 0 1 ) .T h er e l a t i v ei n c r e a s ew a s
higher during LS intake than during HS intake (1.1%
(SD 0.5) vs. 0.4% (SD 0.6), P < 0.001).
P-Na increased in response to the hypertonic saline
infusion in both groups during both diets with maxi-
mum after 60 minutes. During LS intake the relative
increase in p-Na was slightly but significantly higher in
the patients compared to the controls (3.6% (SD 0.9) vs.
3.0% (SD 0.9), P = 0.039). The relative increases were
not significantly different between HS and LS intake in
any of the two groups.
P-albumin fell significantly in response to the hyper-
tonic saline infusion in both groups during both diets to
comparable levels at the end of the study day (data not
shown). The decrease was significantly higher during LS
intake.
GFR
During LS intake, the hypertonic saline infusion caused
as i g n i f i c a n td e c r e a s ei nG F Ri nt h ep a t i e n tg r o u p6 0
minutes after infusion start (Table 6). The difference in
the reductions in GFR between the two diets was not
statistically significant (P = 0.688).
Discussion
In the present study, we compared u-AQP2CR and u-
ENaCb-CR in patients with essential hypertension and
normotensive control subjects during HS and LS intake.
Furthermore, we compared the relative change in u-
AQP2CR and u-ENaCb-CR in response to a hypertonic
saline infusion in patients and controls. U-AQP2CR and
u-ENaCb-CR were normal in essential hypertension at
baseline. However, in response to the hypertonic saline
infusion, u-AQP2CR was abnormally increased in essen-
tial hypertension, whereas the response in u-ENaCb-CR
was normal.
U-ENaCb-CR and u-AQP2CR are not increased in essential
hypertension at baseline
Both the systolic and the diastolic blood pressures were
significantly higher in the patients than in the normo-
tensive controls during both diets as expected. The sub-
jects were studied in the supine position, which explains
the rather low blood pressure levels in both groups
throughout the study days.
Surprisingly, and in contrast with results from experi-
mental models of hypertension [16-18,33,34] and patient
with essential hypertension carrying polymorphisms of
adducin [35], we found that u-ENaCb-CR and u-AQP2CR
were not abnormal in patients with essential hyperten-
sion. U-osm, V, UNa,a n dF E Na were similar in patients
with essential hypertension and normotensive controls
during both HS and LS intake.
Thus, altogether these results indicate that the expres-
sion of AQP2 and the expression of ENaC are not
increased in essential hypertension.
AVP and u-cAMP were not increased in the patients
with essential hypertension compared to the normoten-
sive controls during any of the diets. The activity of the
renin-angiotensin-aldosterone system has previously
been reported to be suppressed in hypertensive patients
compared with normotensive controls during low and
normal sodium intakes [36]. In the present study, Ang
II was suppressed in patients compared with controls
but only during HS intake. PRC and Aldo were similar
in patients and controls during both diets. We cannot
explain the discrepancy between the two studies. Thus,
apart from Ang II, the levels of the main hormonal reg-
ulators of the expression of AQP2 and ENaC are similar
in patients with essential hypertension and normotensive
controls.
We found a significantly lower u-AQP2CR during LS
intake than during HS intake in both groups and a con-
comitant significantly lower V during LS intake.
Recently, our group reported lower AQP2 during LS
intake compared to during HS intake in young healthy
subject, in agreement with the present study [37]. In the
previous study, we discussed the possibility that an
increase in the reabsorption of water proximal in the
nephron during LS intake was followed by a fine-tuning
in the collecting duct principal cells with decreased
expression of AQP2 [37]. In support of this, Kulick et
al. measured a higher absolute fluid reabsorption in rat
proximal tubule during LS intake by direct in vivo
microperfusion and recollection. The responsible
mechanism was the adenosine type 1 receptor [38].
One should remember that both patients and control
subjects were water loaded in order to make urine col-
lection possible. We believe that this is the reason for
the low osmolalities during the first hours of the study
days.
We found a significantly lower u-ENaCb-CR during LS
intake compared to during HS intake in the patients
with essential hypertension at baseline, but not in the
normotensive controls. LS intake is known to increase
open probability of ENaC and the number of active
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Page 12 of 15ENaCs in normotensive mice [39]. No difference in u-
ENaCb-CR between HS and LS intake was present in the
patients with essential hypertension during the 24-h
urine collection. Therefore we speculate that the differ-
ence in u-ENaCb-CR between HS and LS intake at base-
line in the patients with essential hypertension could be
by chance.
Abnormally higher increase in u-AQP2CR in response to
hypertonic saline in essential hypertension
U-AQP2CR increased significantly more in response to
the hypertonic saline infusion in patients with essential
hypertension than in normotensive controls, which sug-
gests that the patients reabsorb a larger proportion of
the infused water. Thus, somehow the antidiuretic effect
of the hypertonic saline is increased in essential hyper-
tension. The underlying regulatory mechanism is
unknown. Abnormalities in AVP, PRC, Ang II, Aldo,
ANP, BNP, u-PGE2, u-cAMP, GFR, blood pressure and
heart rate were not responsible for the difference, since
these effect variables changed in similar manner in
patients and controls.
Jackson et al. have previously shown that Ang II has
an enhanced ability to reduce urinary cAMP excretion
in spontaneously hypertensive rats [40]. We speculate,
that the larger increase in u-AQP2 in response to the
hypertonic saline in patients with essential hypertension
could reflect an abnormal increase in cAMP in patients
with essential hypertension in response to the fall in
Ang II. Whether an abnormal sensitivity to Ang II with
regard to inhibiting the adenylyl cyclase is involved in
the pathogenesis of essential hypertension, will be the
subject of future investigations.
To our knowledge this is the first time that the change
in u-AQP2CR in response to a hypertonic saline infusion
has been measured in patients with essential hyperten-
sion. U-AQP2CR increased considerably, but the regula-
tory mechanism is unknown.
Normal response in u-ENaCb-CR to hypertonic saline in
essential hypertension
One would have expected a decrease in u-ENaCb-CR in
response to the hypertonic saline infusion, since Aldo
decreased and UNa and FENa increased in both patients
and controls. Instead we found a small but significant
increase in u-ENaCb-CR in response to the hypertonic
saline. The explanation of this phenomenon is not
c l e a rf o rt h et i m eb e i n g .Aconsiderable decrease in
the renal sodium absorption more proximal in the
nephron might be compensated for by an increase in
absorption in the distal part of the nephron, but addi-
tional studies are required to determine the precise use
of u-ENaCb-CR as biomarker for ENaC activity.
Whether membrane shedding plays a role in the
increase in u-ENaC awaits further studies. A signifi-
cantly higher natriuretic response was observed in the
patients two hours after the hypertonic saline infusion
during HS intake (Table 6). The similar change in the
glomerular filtered load of sodium in patients and con-
trols suggests that a reduction in renal tubular sodium
reabsorption contributes to the higher natriuretic
response in patients with essential hypertension during
HS intake. ENaC does not seem to be responsible for
the decreased tubular sodium reabsorption, since the
change in ENaC in response to the hypertonic saline
infusion was similar in patients and controls. The sys-
tolic blood pressure increased significantly during HS
intake in the patients, but not in the controls, and
could have contributed to the higher natriuretic
response. The exaggerated natriuretic response in
essential hypertensive patients has been reported in
numerous studies. It has been attributed both to
altered handling of sodium in both proximal and distal
tubules, to an exaggerated increase in ANP, and to an
increased GFR, but the exact intra-renal mechanism is
unknown. However, the response in u-ENaCb-CR to
hypertonic saline infusion was the same in patients
with essential hypertension and normotensive controls.
Thus, an abnormal regulation of ENaC could not
explain the phenomenon of exaggerated natriuresis in
essential hypertension.
Strength and limitations
The strengths of this study lie in the design. The study
is a controlled clinical study with an age- and sex-
matched control group. The salt intake and fluid intake
are standardised and controlled. Furthermore the
patients with essential hypertension pause their antihy-
pertensive medication during the study. Thus, the
results are not confounded by different salt or water bal-
ance or antihypertensive drugs.
A limitation of the study is that the threshold for
hypertension is quite modest, which may explain why
few differences are seen. We cannot exclude that we
would have found a more pronounced difference in the
AQP2 response to the hypertonic saline between
patients and controls, if we had included patients with
more severe hypertension.
Conclusions
In conclusion, no difference was found in u-AQP2CR
and u-ENaCb-CR between patients and controls at base-
line. However, in response to the hypertonic saline infu-
sion, u-AQP2CR was abnormally increased in essential
hypertension, whereas the response in u-ENaCb-CR was
normal. The underlying mechanism for the abnormal
Graffe et al. BMC Nephrology 2012, 13:15
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Page 13 of 15regulation of AQP2 expression is not clarified, but it is
not AVP-dependent.
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